Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pain drug shows promise for bunion surgery recovery

NCT ID NCT02762929

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental pain medication called HTX-011 in 430 adults recovering from bunion surgery. The goal was to see if it reduces pain better than standard treatments. Participants received the drug locally at the surgery site, and pain levels were tracked for 24 hours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

430 people

The number who actually took part.

Started

May 2016

Finished

Mar 2017

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be male or female 18 years of age or older 2. Female subjects are eligible only if all of the following apply: 1. Not pregnant (female subject of child bearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test before surgery) 2. Not lactating 3. Not planning to become pregnant while participating in the study 4. Be surgically sterile; or be at least two years post-menopausal; or have a monogamous partner who is surgically sterile; or be practicing double-barrier contraception; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to screening visits and commits to the use of an acceptable form of birth control for the duration of the study and for 30 days from completion of the study 3. Male subjects must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 1 week after the administration of study medication 4. Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia 5. Subject has not had a contralateral bunionectomy in the non-study foot in the past 3 months 6. Have the ability and be willing to comply with the study procedures. 7. Must be able to understand study procedures and give informed consent for the conduct for all study procedures, using an IRB approved consent form Exclusion Criteria: 1. Unwilling to sign informed consent or not willing or able to complete all study procedures 2. Have a contraindication or be allergic to any medication to be used during the trial period 3. Have clinically significant cardiac abnormalities that, in the opinion of the investigator, would pose a health risk to the subject 4. Have American Society of Anesthesiologists (ASA) Physical Status classification system category ≥4 5. Have clinically significant renal or hepatic abnormalities: for example, AST or ALT \> 3x ULN, creatinine \> 2x ULN 6. Have another pre-existing painful condition that may confound pain assessments 7. Have another surgery planned within 30 days of procedure 8. Have a known or suspected history of alcohol or drug abuse, or a positive drug screen 9. Currently taking analgesics for a chronically painful condition, or has taken long acting opioids within 3 days of surgery, or taken any opioids within 24 hours of scheduled surgery for this study 10. Subjects with documented sleep apnea or are on home continuous positive airway pressure (CPAP) 11. Subjects who are receiving oxygen therapy at the time of screening 12. Have participated in a clinical trial within 30 days of planned surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bunions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia Bunion Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Study site

    Anaheim, California, 92801, United States

  • Study site

    Bakersfield, California, 93311, United States

  • Study site

    Pasadena, Maryland, 21122, United States

  • Study site

    Houston, Texas, 77027, United States

  • Study site

    San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.